Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

医学 柔红霉素 诱导化疗 随机对照试验 内科学 白血病 肿瘤科 外科 化疗
作者
Christoph Röllig,Björn Steffen,Christoph Schliemann,Jan-Henrik Mikesch,Nael Alakel,Regina Herbst,Mathias Hänel,Richard Noppeney,Maher Hanoun,Martin Kaufmann,Barbora Weinbergerová,Kerstin Schäfer‐Eckart,Tim Sauer,Andreas Neubauer,Andreas Burchert,Claudia D. Baldus,Jolana Mertová,Edgar Jost,Dirk Niemann,Jan Novák
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
被引量:3
标识
DOI:10.1200/jco.24.00235
摘要

PURPOSE To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m 2 with 90 mg/m 2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction. PATIENTS AND METHODS Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m 2 daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle. RESULTS Eight hundred and sixty-four patients with a median age of 52 years were randomly assigned. After a preplanned interim analysis showing no significant difference in response between 60 and 90 mg/m 2 , all consecutive patients received 60 mg/m 2 daunorubicin once daily. The proportion of good early responders was 44% versus 48% ( P = .983) with a composite complete remission (CRc) rate of 90% versus 89% after induction ( P = .691); the 3-year relapse-free survival (RFS) after 60 versus 90 mg/m 2 once daily was 54% versus 50% ( P = .561), and the 3-year overall survival (OS) was 65% versus 58% ( P = .242). Among 389 good responders, CRc rates at the end of induction were 87% after single induction and 85% after double induction. The 3-year RFS was 51% versus 60% (hazard ratio [HR], 1.3; P = .091), and the 3-year OS was 76% versus 75% after single versus double induction (HR, 1.0; P = .937). CONCLUSION The use of 90 mg/m 2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m 2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ash发布了新的文献求助10
刚刚
科研通AI5应助哭泣笑柳采纳,获得10
刚刚
倾听阳光完成签到 ,获得积分10
1秒前
iPhone7跑GWAS完成签到,获得积分10
1秒前
chinbaor完成签到,获得积分10
3秒前
怡然猎豹完成签到,获得积分10
4秒前
songvv发布了新的文献求助10
4秒前
ash完成签到,获得积分10
4秒前
8秒前
shezhinicheng完成签到,获得积分10
8秒前
桃花不用开了完成签到 ,获得积分10
9秒前
futong发布了新的文献求助10
11秒前
张瑞雪完成签到 ,获得积分10
14秒前
666完成签到,获得积分10
15秒前
大模型应助大橙子采纳,获得10
15秒前
maclogos发布了新的文献求助10
16秒前
李燕完成签到,获得积分10
16秒前
hahaha完成签到,获得积分10
17秒前
长长的名字完成签到 ,获得积分10
18秒前
离子电池完成签到,获得积分10
18秒前
futong完成签到,获得积分10
19秒前
量子星尘发布了新的文献求助10
21秒前
CooL完成签到 ,获得积分10
22秒前
科学家发布了新的文献求助10
22秒前
zhang26xian完成签到,获得积分10
25秒前
天真酒窝完成签到,获得积分10
27秒前
CodeCraft应助RC_Wang采纳,获得10
28秒前
流沙无言完成签到 ,获得积分10
28秒前
31秒前
殷启维完成签到,获得积分10
31秒前
禾页完成签到 ,获得积分10
32秒前
非鱼鱼完成签到 ,获得积分10
32秒前
科学家完成签到,获得积分10
32秒前
songvv发布了新的文献求助10
32秒前
阿九完成签到,获得积分10
34秒前
水晶茶杯发布了新的文献求助20
36秒前
37秒前
Cala洛~完成签到 ,获得积分10
38秒前
HH发布了新的文献求助10
38秒前
北海完成签到,获得积分10
40秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022